JP2013523783A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523783A5
JP2013523783A5 JP2013502959A JP2013502959A JP2013523783A5 JP 2013523783 A5 JP2013523783 A5 JP 2013523783A5 JP 2013502959 A JP2013502959 A JP 2013502959A JP 2013502959 A JP2013502959 A JP 2013502959A JP 2013523783 A5 JP2013523783 A5 JP 2013523783A5
Authority
JP
Japan
Prior art keywords
hiv
fragment
env
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013502959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523783A (ja
JP6026402B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000407 external-priority patent/WO2011123900A1/en
Publication of JP2013523783A publication Critical patent/JP2013523783A/ja
Publication of JP2013523783A5 publication Critical patent/JP2013523783A5/ja
Application granted granted Critical
Publication of JP6026402B2 publication Critical patent/JP6026402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013502959A 2010-04-09 2011-04-11 Hivの伝染を抑制する方法及び組成物 Expired - Fee Related JP6026402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
US61/322,399 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (3)

Publication Number Publication Date
JP2013523783A JP2013523783A (ja) 2013-06-17
JP2013523783A5 true JP2013523783A5 (enExample) 2014-05-29
JP6026402B2 JP6026402B2 (ja) 2016-11-16

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502959A Expired - Fee Related JP6026402B2 (ja) 2010-04-09 2011-04-11 Hivの伝染を抑制する方法及び組成物

Country Status (12)

Country Link
US (1) US20130022619A1 (enExample)
EP (1) EP2555798B1 (enExample)
JP (1) JP6026402B2 (enExample)
CN (1) CN103167881B (enExample)
AP (1) AP3469A (enExample)
AU (2) AU2011238431B2 (enExample)
BR (1) BR112012025678A2 (enExample)
CA (1) CA2795853A1 (enExample)
MX (1) MX343505B (enExample)
RU (1) RU2594249C2 (enExample)
WO (1) WO2011123900A1 (enExample)
ZA (1) ZA201207790B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077130B2 (en) 2013-09-27 2021-08-03 Duke University Methods for reducing HIV-1 mother-to-child transmission by inducing V3-specific or CD4 binding site-specific antibodies
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
RU2757135C2 (ru) * 2015-09-24 2021-10-11 АБВИТРО ЭлЭлСи Композиции антител к вич и способы их применения
WO2017062070A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless compact torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
AU2021289612A1 (en) * 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
IL308087A (en) 2021-05-12 2023-12-01 Applied Biomedical Science Inst Methods for the screening and expression of disulfide-bonded polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
AU2023379740A1 (en) 2022-11-16 2025-05-29 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
JP4880153B2 (ja) * 1999-06-24 2012-02-22 ザ ジョンズ ホプキンス ユニヴァーシティ Hivの経上皮伝染を予防する組成物および方法
JP2004509914A (ja) * 2000-09-28 2004-04-02 カイロン コーポレイション 微粒子組成物およびその製造方法
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
AU2008318677A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as HIV-1 vaccines
EP2349333A4 (en) * 2008-10-30 2012-08-29 Dana Farber Cancer Inst Inc MIMOTOPES OF ENV HIV

Similar Documents

Publication Publication Date Title
JP2013523783A5 (enExample)
JP2017035093A5 (enExample)
WO2017123636A8 (en) Dosage and administration of anti-c5 antibodies for treatment
CY1123462T1 (el) Αντισωματα που εξουδετερωνουν ισχυρα τον ιο ηπατιτιδας β και χρησεις αυτων
CY1124618T1 (el) Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
JP2018064580A5 (enExample)
EP2601969A3 (en) Norovirus vaccine formulations
JP2017507117A5 (enExample)
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN106659777A8 (zh) 免疫原性组合产品
Lai et al. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1
EA201200277A1 (ru) Антитела против респираторного синцитиального вируса (pcb) и способы их применения
JP2010521147A5 (enExample)
HK1254950A1 (zh) 中和人体呼吸道合胞体病毒的抗体
WO2007081447A3 (en) Norovirus and sapovirus antigens
JP2017524339A5 (enExample)
JP2014237714A5 (enExample)
WO2013063366A3 (en) Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
EP4292659A3 (en) Antibodies that neutralize hepatitis b virus and uses thereof
JP2015524422A5 (enExample)
JP2017526689A5 (enExample)
EA200900033A1 (ru) Вакцины против малярии
Tong et al. Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus